Obesity Management

CME Travel Academy clinical update graphic: oral GLP-1 treatment for obesity, orforglipron, SELECT trial, 20% MACE risk reduction, 11.2% weight loss, 12 CME hours

Oral GLP-1 Treatment for Obesity: Orforglipron, the SELECT Trial, and the New 2026 Primary Care Playbook

By Dr. Vimal George, MD | Reviewed by CME Travel Academy Faculty8 min read  ·  Reviewed July 2026 Accredited CME: ✓ AMA PRA Category 1 Credit™ ✓ AAFP Prescribed ✓ AOA Category 2 ✓ 12 Credits per Conference In this article: Obesity Is Now a Cardiovascular Diagnosis Orforglipron Changes the Access Equation Injectable Incretins Still

Oral GLP-1 Treatment for Obesity: Orforglipron, the SELECT Trial, and the New 2026 Primary Care Playbook Read More »

GLP-1 Receptor Agonists in Obese HFpEF: What the STEP-HFpEF and SUMMIT Trials Mean for Your Practice

Heart failure with preserved ejection fraction (HFpEF) now accounts for more than half of all heart failure diagnoses in the United States, and the proportion continues to rise alongside the obesity epidemic. For decades, clinicians managing this phenotype had few effective pharmacologic tools — spironolactone and SGLT-2 inhibitors offered modest benefit in selected patients, but

GLP-1 Receptor Agonists in Obese HFpEF: What the STEP-HFpEF and SUMMIT Trials Mean for Your Practice Read More »